AMR Logo.png
2027 년까지 세계 혈액 은행 시장에 $ 21.86 십억 : AMR
June 08, 2020 09:00 ET | Allied Market Research
Portland, OR, June 08, 2020 (GLOBE NEWSWIRE) -- 이 보고서에 따르면, 세계 혈액 은행 시장은 2019 년에 1,385 억 달러를 창출했으며, 2027 년에서 2027 년에서 2027 년까지 연평균 5.7 % 성장한 2027 년까지 218 억 8 천만 달러를 기록 할 것으로 예상됩니다. 포켓, 추진 요인 및 기회,...
AMR Logo.png
Global Blood Bank Market to Garner $21.86 Billion by 2027: AMR
June 08, 2020 09:00 ET | Allied Market Research
Portland, OR, June 08, 2020 (GLOBE NEWSWIRE) -- According to the report, the global blood bank market generated $13.85 billion in 2019, and is expected to garner $21.86 billion by 2027, witnessing a...
Zero Sweat, Neon Sweat, Mega Sweat, Smelly Sweat & Bloody Sweat
January 30, 2020 11:50 ET | International Hyperhidrosis Society
Center Valley, PA, Jan. 30, 2020 (GLOBE NEWSWIRE) -- Sweat is essential to human survival, but when sweating is "different," serious issues come up -- like health concerns, lack of awareness and...
ExCellThera enters i
ExCellThera enters into a manufacturing and collaboration agreement with New York Blood Center
May 07, 2019 08:05 ET | ExCellThera
MONTREAL, May 07, 2019 (GLOBE NEWSWIRE) -- ExCellThera Inc., an advanced clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for...
ExCellThera’s lead t
ExCellThera’s lead technology, ECT-001, receives FDA Regenerative Medicine Advanced Therapy (RMAT) designation   
April 23, 2019 08:05 ET | ExCellThera
MONTREAL, April 23, 2019 (GLOBE NEWSWIRE) -- ExCellThera Inc., an advanced clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for...
logo-small.jpg
Novel treatment of hemophilia: OMRF enters license agreement with Shanghai RAAS Blood Products
February 13, 2018 15:02 ET | Oklahoma Medical Research Foundation
OKLAHOMA CITY, Feb. 13, 2018 (GLOBE NEWSWIRE) -- The Oklahoma Medical Research Foundation has entered a license agreement with Shanghai RAAS Blood Products Co., Ltd. Under the agreement, Shanghai...
BFNH.jpg
BioForce Nanosciences Holdings, Inc. (BFNH) Moves Forward With Uplifting Requirements for OTCQB, Aggressively Pursues Take Over Targets
October 18, 2017 09:15 ET | BioForce Nanosciences Holdings, Inc.
VIRGINIA BEACH, Va., Oct. 18, 2017 (GLOBE NEWSWIRE) -- BioForce Nanosciences Holdings, Inc. (OTCPINK:BFNH) announces its pursuit to uplift the Company’s tradable common shares onto the OTCQB at...
Typenex® Medical Brings Innovative Blood Irradiation Indicator to Market
September 06, 2017 09:33 ET | Typenex Medical
CHICAGO, Sept. 06, 2017 (GLOBE NEWSWIRE) -- Typenex Medical, an industry leader in medical devices and supplies, announced today it is bringing Rad-Control, a new irradiation indicator tag...
Arch Therapeutics Announces 510(k) Submission to the U.S. FDA for AC5(TM) Topical Gel
July 25, 2017 07:55 ET | Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Jul 25, 2017) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, today...
Arch Therapeutics Presents Corporate Update at the LD Micro Invitational on Tuesday, June 6, 2017
June 06, 2017 12:25 ET | Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Jun 6, 2017) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, today...